Immunology of HCV and HBV in Renal Failure and Transplantation

作者: A Karami , A Najafi , M Y Kiaroudi , S M Alavian

DOI:

关键词:

摘要: B hepatitis C virus (HCV) and (HBV) infections are common in patients with end-stage renal disease (ESRD) transplant recipients (1-4). Although both viral replication liver progression accelerated after transplantation, the subsequent long-term impact of chronic HBV HCV is unclear. Chronic failure at particular risk infection. Early studies have demonstrated that benefit from vaccination; however, not all consistently shown benefit. infection among ESRD (5, 6). However, effect on survival patients, transplantation course been adequately defined. The primary goal treatment should be eradication Secondary aims prevention decompensated cirrhosis or hepatocellular carcinoma through sustained suppression. When determining optimal regimen, several questions must addressed which antiviral agents, whom to treat, when start therapy. Interferon has direct potent immunomodulatory actions (7). Development screening serological tests for detection significantly reduced incidence rates these (8). resulting still a major concern kidney (9). It certain immunosuppressive agents facilitate higher

参考文章(45)
F. Degos, C. Lugassy, C. Degott, A. Debure, F. Carnot, V. Thiers, P. Tiollais, H. Kreis, C. Brechot, Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients: A prospective study of 90 patients Gastroenterology. ,vol. 94, pp. 151- 156 ,(1988) , 10.1016/0016-5085(88)90623-3
C Willberg, E Barnes, P Klenerman, HCV immunology--death and the maiden T cell. Cell Death & Differentiation. ,vol. 10, ,(2003) , 10.1038/SJ.CDD.4401122
Elaine R. Miller, Miriam J. Alter, Jerome I. Tokars, Protective effect of hepatitis B vaccine in chronic hemodialysis patients American Journal of Kidney Diseases. ,vol. 33, pp. 356- 360 ,(1999) , 10.1016/S0272-6386(99)70312-4
PING-NAM WONG, TANG-TAT FUNG, SIU-KA MAK, KIN-YEE LO, GENSY MW TONG, YUK WONG, CHING-KONG LOO, ERIC KM LAM, ANDREW KM WONG, Hepatitis B virus infection in dialysis patients Journal of Gastroenterology and Hepatology. ,vol. 20, pp. 1641- 1651 ,(2005) , 10.1111/J.1440-1746.2005.03837.X
Touru Hanafusa, Yasuji Ichikawa, Hidefumi Kishikawa, Masahiro Kyo, Takanobu Fukunishi, Yukito Kokado, Akihiko Okuyama, Yoshitake Shinji, Shunsuke Nagano, Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation. ,vol. 66, pp. 471- 476 ,(1998) , 10.1097/00007890-199808270-00010
T.K. Blackmore, N.H. Stace, P. Maddocks, P. Hatfield, Prevalence of antibodies to hepatitis C virus in patients receiving renal replacement therapy, and in the staff caring for them Australian and New Zealand Journal of Medicine. ,vol. 22, pp. 353- 357 ,(1992) , 10.1111/J.1445-5994.1992.TB02147.X
Michael von Wagner, Miriam Huber, Thomas Berg, Holger Hinrichsen, Jens Rasenack, Tobias Heintges, Alexandra Bergk, Christine Bernsmeier, Dieter Häussinger, Eva Herrmann, Stefan Zeuzem, Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C Gastroenterology. ,vol. 129, pp. 522- 527 ,(2005) , 10.1053/J.GASTRO.2005.05.008
Sophie Fornairon, Stanislas Pol, Christophe Legendre, Fran??oise Carnot, Marie-France Mamzer-Bruneel, Christian Brechot, Henri Kreis, The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation. ,vol. 62, pp. 297- 299 ,(1996) , 10.1097/00007890-199607270-00025
T Tokumoto, K Tanabe, N Ishikawa, T Simizu, T Oshima, S Noguchi, N Gouya, H Nakazawa, E Hashimoto, S Fuchinoue, N Hayashi, H Toma, Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. International Alexis Carrel Conference. ,vol. 31, pp. 2887- 2889 ,(1999) , 10.1016/S0041-1345(99)00603-X